- ►annals.org [PDF] Y Shiratori, Y Ito, O Yokosuka, F Imazeki, R … - Annals of internal medicine, 2005 - Am Coll Physicians Patients: 345 patients with chronic hepatitis C and cirrhosis enrolled in
previous trials. Intervention: 271 patients received 6 to 9 million U of inter-
feron 3 times weekly for 26 to 88 weeks; 74 received no treat- ment. ... Cited by 84 - Related articles - All 5 versions
- ►oxfordjournals.org Y Shiratori, H Yoshida, M Omata - Japanese Journal of Clinical Oncology, 2000 - FPCR The natural history of chronic HCV infection suggests that there is a sequential
but slow progression from acute HCV infection to chronic infection, leading to
cirrhosis and death from either liver failure or hepatocellular carcinoma ... Related articles - BL Direct - All 4 versions
- ►bmj.com BJ Veldt, G Saracco, N Boyer, C Camma, A … - British Medical Journal, 2004 - gut.bmj.com Background: The key end point for treatment efficacy in chronic hepatitis C is
absence of detectable virus at six months after treatment. However, the
incidence of clinical events during long term follow up of patients with ... Cited by 69 - Related articles - BL Direct - All 11 versions
- ►bmj.com H Yoshida, R Tateishi, Y Arakawa, M Sata, S … - British Medical Journal, 2004 - gut.bmj.com Background: An increase in the incidence of hepatocellular carcinoma (HCC) in
Japan since the 1980s suggests an imminent outbreak in other countries where
viral spread occurred more recently. Interferon therapy for chronic ... Cited by 60 - Related articles - BL Direct - All 10 versions
F Imazeki, O Yokosuka, K Fukai, H Saisho - Hepatology, 2003 - hepatitis-central.com The prognosis of patients with chronic hepatitis C after interferon (IFN)
therapy is still poorly defined. The present study evaluated the effect of IFN
therapy on survival in a cohort of such patients. The study included 459 ... Cited by 42 - Related articles - View as HTML - All 5 versions
- ►bmj.com A Gramenzi, P Andreone, S Fiorino, C Camma, M … - British Medical Journal, 2001 - gut.bmj.com PATIENTS We conducted a non-randomised prospective controlled trial at the
Department of Internal Medicine, Cardioangiology and Hepatology, University of
Bologna, that serves as a tertiary referral centre. Seventy two patients ... Cited by 52 - Related articles - BL Direct - All 8 versions
S Bruno, PM Battezzati, G Bellati, A Manzin, … - Journal of hepatology, 2001 - Elsevier Results: The mean follow-up was 102±19 months. HCV RNA became undetectable in
36/47 responders. Four responders, who had remained viremic, later relapsed. The
histology progressively improved in non-viremic and viremic patients, with ... Cited by 44 - Related articles - BL Direct - All 6 versions
C Cammā, M Giunta, P Andreone, A Craxė - Journal of Hepatology, 2001 - Elsevier Methods: Three randomized controlled trials and 15 nonrandomized controlled
trials, including 4614 patients and comparing IFN to no treatment, were
selected. Data on the incidence of HCC in IFN treated and untreated ... Cited by 220 - Related articles - BL Direct - All 5 versions
M Omata, Y Shiratori - J Gastroenterol Hepatol, 2000 - interscience.wiley.com Chronic hepatitis C is a common disease that slowly progresses to cirrhosis and
eventually to hepatocellular carcinoma (HCC). Histology offers an important
insight into disease prognosis and treatment response. Biochemical and ... Cited by 23 - Related articles - BL Direct - All 2 versions
- ►bmj.com F Degos, C Christidis, N Ganne-Carrie, JP … - British Medical Journal, 2000 - gut.bmj.com Hepatitis C virus (HCV) infection has become a major worldwide health problem
because of the potential natural course of the disease to cirrhosis and then
hepatocellular carcinoma (HCC). 1-14 At the present time, HCV related ... Cited by 155 - Related articles - BL Direct - All 9 versions
